Lilly’s Alzheimer’s Struggles Continue as Preclinical Disease Asset Fails Phase III

Data released Wednesday from the Phase III A4 study showed solanezumab fell short of its primary endpoint, failing to slow cognitive decline in patients with preclinical Alzheimer’s disease.